Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Enovis Corp (ENOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ENOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.7% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 56.5 |
Price to earnings Ratio - | 1Y Target Price 56.5 | ||
Volume (30-day avg) 1281066 | Beta 1.83 | 52 Weeks Range 29.13 - 49.83 | Updated Date 06/19/2025 |
52 Weeks Range 29.13 - 49.83 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.65% | Operating Margin (TTM) 0.9% |
Management Effectiveness
Return on Assets (TTM) 0.92% | Return on Equity (TTM) -27.35% |
Valuation
Trailing PE - | Forward PE 9.99 | Enterprise Value 3171800743 | Price to Sales(TTM) 0.82 |
Enterprise Value 3171800743 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 1.48 | Enterprise Value to EBITDA 22.42 | Shares Outstanding 57123100 | Shares Floating 56402729 |
Shares Outstanding 57123100 | Shares Floating 56402729 | ||
Percent Insiders 1.54 | Percent Institutions 117.93 |
Analyst Ratings
Rating 4.55 | Target Price 56.5 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enovis Corp
Company Overview
History and Background
Enovis Corp, formerly known as Colfax Corporation, was founded in 1995. Initially focused on industrial manufacturing, it transformed into a medical technology company through strategic acquisitions, primarily in the orthopedic and rehabilitation markets. The company rebranded as Enovis Corp in 2022 to reflect its healthcare focus.
Core Business Areas
- Prevention & Recovery: This segment focuses on bracing, rehabilitation, and performance solutions, targeting a broad spectrum of patient needs from injury prevention to post-operative recovery. The product offerings include bracing and support products, hot and cold therapy systems, and clinical rehabilitation equipment.
- Reconstructive: This segment offers implants and surgical solutions for joint reconstruction and fixation, specifically focusing on extremities. It provides products for the shoulder, knee, hip, and foot and ankle markets.
Leadership and Structure
The leadership team is headed by Matt Trerotola as CEO. The organizational structure is divided by the business segments and functional departments such as R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- DJO Surgical: DJO Surgical offers a comprehensive portfolio of orthopedic reconstruction, trauma, extremities, and spine solutions. Competitors include Stryker, Zimmer Biomet, and Smith+Nephew. Market share information is not publicly segmented in a detailed manner for this specific product line but is a key player in the company's reconstructive segment revenue.
- DJO Bracing and Supports: DJO is a leading provider of bracing and support products used for injury prevention and rehabilitation. Competitors include Bauerfeind, Breg, and Ossur. DJO accounts for around ~30% of global bracing and supports market. The global bracing and supports market is predicted to reach USD 5.2 Billion by 2028.
Market Dynamics
Industry Overview
The medical technology industry, particularly the orthopedic and rehabilitation sectors, is experiencing growth driven by an aging population, increasing prevalence of chronic conditions, and advancements in medical technology. Demand for less invasive surgical procedures and personalized treatment solutions is also rising.
Positioning
Enovis Corp is positioned as a leading provider of orthopedic and rehabilitation solutions, emphasizing innovation, a comprehensive product portfolio, and a focus on patient outcomes. Its competitive advantage lies in its strong brand recognition, established distribution channels, and a diverse product offering.
Total Addressable Market (TAM)
The total addressable market for orthopedic and rehabilitation products is estimated to be in the tens of billions of dollars globally. Enovis Corp is positioned to capture a significant share of this market by offering a broad range of solutions and targeting both preventative and reconstructive segments.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Comprehensive product portfolio
- Established distribution channels
- Focus on innovation
- Global presence
Weaknesses
- High debt levels
- Dependence on acquisitions for growth
- Integration risks associated with acquisitions
- Exposure to reimbursement pressures
Opportunities
- Expanding into emerging markets
- Developing new and innovative products
- Acquiring complementary businesses
- Leveraging digital technologies
- Partnerships with leading institutions
Threats
- Increasing competition
- Changing regulatory landscape
- Pricing pressures
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- STRY
- ZBH
- BSX
- SNY
Competitive Landscape
Enovis competes with larger, more diversified medical technology companies. Its advantages include a focus on specific market segments and a strong innovation pipeline. Disadvantages include smaller scale and higher debt levels.
Major Acquisitions
acquired MedShape Solutions, Inc.
- Year: 2019
- Acquisition Price (USD millions): 85
- Strategic Rationale: Acquisition of MedShape expanded Enovis' portfolio of solutions for foot and ankle surgery.
Growth Trajectory and Initiatives
Historical Growth: Enovis has grown both organically and through acquisitions. The growth rate has fluctuated depending on economic conditions and the timing of acquisitions.
Future Projections: Analyst projections vary, but generally anticipate continued growth in revenue and earnings. These projections are based on market trends, industry growth rates, and company-specific initiatives.
Recent Initiatives: Recent initiatives include strategic acquisitions, product launches, and investments in research and development.
Summary
Enovis is a focused medical technology company with a strong presence in the orthopedic and rehabilitation markets. The company's comprehensive product portfolio, coupled with strategic acquisitions, has enabled consistent growth. High debt levels and strong competition are risks. It is important for Enovis to drive organic growth, continue to innovate, and effectively manage debt.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Website
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enovis Corp
Exchange NYSE | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2008-05-08 | CEO & Director Mr. Damien McDonald | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7367 | Website https://www.enovis.com |
Full time employees 7367 | Website https://www.enovis.com | ||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.